Wellcome letter


Hi to all of our followers! First of all I have to thank all of you for letting me take care of your health and lifestyle. Hopefully you have found some answers to your problems and are well on your way to a healthier you or hopefully you are already on a maintenance plan facing your relationship with food and the scale in a new amicable way. As I probably commented before, I am starting a new way of anonymous communication with all of you. There is a lot of information to be shared as well as a lot of experience and tips that can benefit most of us. As all of you know, I insist and always recommend to be part of a support group, one of the keys to success and one of the main pillars of Lifestyle Intervention for Weight Loss. You also know that I can not share individual information. This blog will be a way of having that. I invite you all to participate and post your experience without sharing any of your personal information. My second intention is to share as much medical/nutritional information as I can. The more educated you become the easier it will be to understand what you are going through.



Link: http://www.lifestylemedicinespecialists.com/







Thursday, September 18, 2014

More good news

More good news in Obesity Medicine, please take a look. This is a piece of an article from the Obesity Society newsletter directed to the medical community.
Enjoy!


September brings two major milestones for obesity treatment 
Letter from the Executive Director
Dear Colleagues,


Last week was an exciting week for obesity treatment. The FDA acted twice in favor of
 expanding needed obesity treatment options — action that will bring new tools for 
clinicians treating the disease, and for millions of people affected.

1) On Wednesday (9/10), FDA approved the new drug treatment, Contrave™, for
 the long-term medical treatment of obesity in adults. Contrave (combination of 
naltrexone sustained release [SR] and bupropion [SR]) is a drug developed by 
Orexigen Therapeutics, Inc. and will be marketed by Takeda Pharmaceutical 
Company Limited. It is expected to be available on pharmacy shelves this fall, and —
 like all obesity medications — is considered an adjunct to diet and exercise.
2) The very next day (Thursday, 9/11) an expert advisory committee appointed
 by the FDA voted by an overwhelming margin of 14-1 to recommend approval
 of a Novo Nordisk drug, liraglutide 3mg (proposed brand name Saxenda®), for
 obesity treatment. The Committee agreed liraglutide 3mg has a favorable benefit/risk 
profile for the treatment of obesity. The next step for this medication will be a final ruling
 by the FDA, which is due in October. Currently, liraglutide is approved and marketed under
 the brand name Victoza® at doses of 0.6, 1.2, and 1.8mg for the treatment of type 2 diabetes.
Posted by at No comments:

Monday, January 13, 2014

News from a Lifestyle friend

Hi everyone! Sorry I have not posted anything in such a long time.
This time I have no miracle news to share with you but just a link to one of our dear friend's new blog. Please visit it, it will give you a new look on disease and their circumstances. The interest in sharing this link is not only to advertise our friend's blog but for you to see that weight is not just an aesthetic problem, actually, that is the last and least of our concern about it. It is linked to disease that does not even cross our minds ( well, it does cross mine, that is why I'm your physician) or the mind of the one carrying the weight. The blog talks about a patient's perspective on a recent serious diagnosis and his own experience going through it. It is worth the time, I promise.  I have to tell you also that I am including this link and related information with the permission of the author.  You will also find the link on the list of links at the bottom of the blog page.

bthumor.wordpress.com

Dr P
Posted by at No comments:
Subscribe to: Posts (Atom)